KRAS and non-small cell lung carcinoma: Moreover, our analysis of the 2018 MSKCC trail data also revealed a similar result, showing that KRAS-mutant NSCLC achieved the best efficacy while EGFR-mutant NSCLC showed the lowest response rate in all groups.